Phase 1
Completed N=153
Nivolumab (BMS-936558; MDX-1106) in Combination With Sunitinib, Pazopanib, or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma (RCC) (CheckMate 016)
Source: ClinicalTrials.gov NCT01472081 ↗Enrolled (actual)
153
Serious AEs
62.1%
Results posted
Aug 2019
Primary outcomePrimary: Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation — 3; 16; 13; 29 participants
Summary
The purpose is to determine the safety, effectiveness and best dose to use when giving Nivolumab in combination with Sunitinib, Pazopanib, or Ipilimumab for the treatment of metastatic renal cell carcinoma.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With AEs, SAEs, and AEs Leading to Discontinuation |
3; 16; 13; 29; 30; 4 | — |
| SECONDARY Best Overall Response Rate (BOR) |
1; 0; 1; 5; 0; 0 | — |
| SECONDARY Objective Response Rate (ORR) |
85.7; 42.3; 45.0; 40.4; 40.4; 0 | — |
| SECONDARY Duration of Response (DOR) |
45.6; 78.1; 30.1; 88.7; 85.9; NA | — |
| SECONDARY Rate of Progression-free Survival (PFS) at Week 24 |
100; 72.9; 54.9; 55.6; 63.8; NA | — |
| SECONDARY Progression-free Survival (PFS) |
11.3; 12.7; 7.2; 7.7; 9.4; 8.5 | — |
Eligibility Criteria
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion Criteria
- Subjects with histological confirmation of RCC
- Advanced or metastatic disease
- Measurable disease as defined by RECIST 1.1 criteria
- Karnofsky Performance Status (KPS) ≥80%
- Available tumor tissue (archival or recent acquisition)
- Subjects enrolled in the I-1, I-3 expansion arms and IN-3 addition arms must not have received any prior systemic therapy for RCC with the following exceptions:
- One prior adjuvant or neoadjuvant therapy for localized or locally advanced RCC is allowed provided recurrence occurred ≥ 6 months after the last dose of the adjuvant or neoadjuvant therapy
- Only prior cytokine based treatment for metastatic RCC [eg, interferon-alpha (IFN-alpha) or interleukin 2 (IL-2)] as prior therapy is allowed
Exclusion Criteria
- Active central nervous system (CNS) metastases
- Active or history of autoimmune disease
- Ongoing symptomatic cardiac dysrhythmias or uncontrolled atrial fibrillation
- History of cerebrovascular accident including transient ischemic attack within the past 12 months
- History of pulmonary embolism or deep vein thrombosis (DVT) within the past 6 months
- Chronic systemic steroids (>10 mg/day Prednisone equivalents) or any other immunosuppressive agents
- White blood cell (WBC) 3x upper limit of normal (ULN)
- Total Bilirubin >1.5x ULN (except subjects with Gilbert syndrome, total bilirubin 1.5x ULN or creatinine clearance <40 mL/min (Cockroft-Gault formula)
Exclusion Criteria for Arm S and Arm P only:
- For dose escalation cohorts - subjects who received prior Sunitinib or Pazopanib and required permanent discontinuation due to toxicity or required dose reduction or delay during the first 12 weeks of therapy due to toxicity, or received both prior Sunitinib and Pazopanib
- Poorly controlled hypertension
- Active bleeding or bleeding susceptibility
Data sourced from ClinicalTrials.gov (NCT01472081). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.